Skip to main content
. 2020 Sep 14;13(9):245. doi: 10.3390/ph13090245

Figure 18.

Figure 18

(a) Formula of an ADC resulting from the stochastic conjugation of dasatinib onto an optimized anti-CXCR4 mAb (HLCX) through a gluthathione sensitive linker, with an average DAR of 3. (b) Formula of an ADC resulting from the site-specific conjugation of a LXR agonist onto an anti-CD11a mutated mAb, with a homogeneous DAR of 2.